Picture EBD Group Asia Bio Partnering Forum 2025 Singapore 650x100px

Collaboration › Details

Bayer–Puhe BioPharma: PRMT5 inhibitor, 202503– license ww excl €na to PH020 / BAY 3713372 from Suzhou Puhe BioPharma Co Ltd

	Period	2025-03-26
	Region	ALL
	Partner, 1st	Suzhou Puhe BioPharma Co.,Ltd.
	Group	Puhe BioPharma (Group)
	Product	BAY 3713372 (formerly PH020, Bayer / Puhe BioPharma)
	Product 2	drug development
	Person	Eckhardt, Jürgen (Bayer 201904 Head of Leaps by Bayer)
	Source	Bayer AG. (3/26/25). "Press Release: Bayer and Puhe BioPharma Enter into Global License Agreement for Clinical Phase I PRMT5 inhibitor [Not intended for U.S. and UK Media]". Berlin & Beijing.

Record changed: 2025-03-31

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x200px

More documents for Bayer (Group)

[1] Bayer AG. (3/26/25). "Press Release: Bayer and Puhe BioPharma Enter into Global License Agreement for Clinical Phase I PRMT5 inhibitor [Not intended for U.S. and UK Media]". Berlin & Beijing....
[2] Boundless Bio, Inc.. (5/16/23). "Press Release: Boundless Bio Announces $100 Million Oversubscribed Series C Financing Co-led by Leaps by Bayer and RA Capital Management". San Diego, CA....
[3] ReCode Therapeutics. (6/29/22). "Press Release: ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M". Menlo Park, CA & Dallas, TX....
[4] Bayer AG. (4/13/22). "Press Release: Bayer Receives Approval for Precision Oncology Treatment Vitrakvi in China [Not intended for U.S. and UK Media]". Berlin....
[5] Bayer AG. (5/27/21). "Press Release: Leaps by Bayer Leads USD 90 Million Series B Financing in Digital Health Company Ada Health". Leverkusen, Berlin & Whippany....
[6] BlueRock Therapeutics LP. (5/17/21). "Press Release: BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases". Cambridge, MA & Madison, WI....
[7] Vividion Therapeutics, Inc.. (2/24/21). "Press Release: Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs". San Diego, CA....
[8] Bayer AG. (1/6/21). "Press Release: Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform". Leverkusen & South San Francisco, CA....
[9] Bayer AG. (9/10/20). "Press Release: Bayer – Supervisory Board Extends CEO Werner Baumann’s Contract until the End of April 2024. Company also Announces Progress in Roundup Settlements". Leverkusen....
[10] Bayer AG. (8/27/20). "Press Release: Bayer and Northpond Ventures Lead USD 55 Million Series A Financing Round for Triumvira Immunologics". Leverkusen & Austin, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]